Prognostic significance of the labeling of Adnab-9 in pancreatic intraductal papillary mucinous neoplasms

Martin Tobi, James Hatfield, Volkan Adsay, Katherine Galagan, Richard Kozarek, Mitsuhiro Inagaki, Shinichi Kasai, Yoshihiko Tokusashi, Takeshi Obara, Ralph H Hruban, John Lough, Alan N. Barkun, Mansour Jabbari, Rafiq Sheikh, Boris Ruebner, Michael J. Lawson, Edgar Ben-Josef, Suzanne Fligiel

Research output: Contribution to journalArticle

Abstract

Background. Pancreatic intraductal papillary mucinous neoplasms (IPMN), morphologically resembling colonic adenomas, often have an indefinable malignant potential. We used a monoclonal antibody (MAb) raised against colonic adenomas, Adnab-9, to identify patients with a better prognosis. Methods. We assessed Adnab-9-labeled sections of these neoplasms from 50 patients, 13 pancreatic adenocarcinomas, and 32 colonic adenomas using standard immunohistochemical techniques. Results. 26% of the IPMNs labeled with Adnab-9 as compared to 0% of pancreatic ductal cancers or surrounding benign tissues, (p <0.001) and 53% of adenomas (p <0.025). Labeling in IPMNs was usually seen in the noninvasive epithelium suggesting that Adnab-9 is a premalignant marker in these lesions. Labeling of invasive IPMN's identified a group of patients with a superior overall survival (p = 0.027). Conclusion. Adnab-9 labeling-characteristics appear similar for both IPMNs and adenomatous polyps, suggesting that they are analogous lesions. Adnab-9 labeling may also be a useful prognostic marker for invasive intraductal papillary mucinous neoplasms.

Original languageEnglish (US)
Pages (from-to)141-150
Number of pages10
JournalInternational Journal of Pancreatology
Volume29
Issue number3
StatePublished - 2001

Fingerprint

Adenoma
Neoplasms
Adenomatous Polyps
Pancreatic Neoplasms
Adnab-9
Adenocarcinoma
Epithelium
Monoclonal Antibodies
Survival

Keywords

  • Colorectal cancer
  • Immunostaining
  • Intraductal papillary mucinous neoplasms
  • Monoclonal antibody
  • Pancreatic ductal cancer
  • Severely dysplastic adenomatous colonic polyps

ASJC Scopus subject areas

  • Gastroenterology
  • Endocrinology
  • Oncology

Cite this

Tobi, M., Hatfield, J., Adsay, V., Galagan, K., Kozarek, R., Inagaki, M., ... Fligiel, S. (2001). Prognostic significance of the labeling of Adnab-9 in pancreatic intraductal papillary mucinous neoplasms. International Journal of Pancreatology, 29(3), 141-150.

Prognostic significance of the labeling of Adnab-9 in pancreatic intraductal papillary mucinous neoplasms. / Tobi, Martin; Hatfield, James; Adsay, Volkan; Galagan, Katherine; Kozarek, Richard; Inagaki, Mitsuhiro; Kasai, Shinichi; Tokusashi, Yoshihiko; Obara, Takeshi; Hruban, Ralph H; Lough, John; Barkun, Alan N.; Jabbari, Mansour; Sheikh, Rafiq; Ruebner, Boris; Lawson, Michael J.; Ben-Josef, Edgar; Fligiel, Suzanne.

In: International Journal of Pancreatology, Vol. 29, No. 3, 2001, p. 141-150.

Research output: Contribution to journalArticle

Tobi, M, Hatfield, J, Adsay, V, Galagan, K, Kozarek, R, Inagaki, M, Kasai, S, Tokusashi, Y, Obara, T, Hruban, RH, Lough, J, Barkun, AN, Jabbari, M, Sheikh, R, Ruebner, B, Lawson, MJ, Ben-Josef, E & Fligiel, S 2001, 'Prognostic significance of the labeling of Adnab-9 in pancreatic intraductal papillary mucinous neoplasms', International Journal of Pancreatology, vol. 29, no. 3, pp. 141-150.
Tobi, Martin ; Hatfield, James ; Adsay, Volkan ; Galagan, Katherine ; Kozarek, Richard ; Inagaki, Mitsuhiro ; Kasai, Shinichi ; Tokusashi, Yoshihiko ; Obara, Takeshi ; Hruban, Ralph H ; Lough, John ; Barkun, Alan N. ; Jabbari, Mansour ; Sheikh, Rafiq ; Ruebner, Boris ; Lawson, Michael J. ; Ben-Josef, Edgar ; Fligiel, Suzanne. / Prognostic significance of the labeling of Adnab-9 in pancreatic intraductal papillary mucinous neoplasms. In: International Journal of Pancreatology. 2001 ; Vol. 29, No. 3. pp. 141-150.
@article{7c3c1559b1f445198c79e25b0740ac46,
title = "Prognostic significance of the labeling of Adnab-9 in pancreatic intraductal papillary mucinous neoplasms",
abstract = "Background. Pancreatic intraductal papillary mucinous neoplasms (IPMN), morphologically resembling colonic adenomas, often have an indefinable malignant potential. We used a monoclonal antibody (MAb) raised against colonic adenomas, Adnab-9, to identify patients with a better prognosis. Methods. We assessed Adnab-9-labeled sections of these neoplasms from 50 patients, 13 pancreatic adenocarcinomas, and 32 colonic adenomas using standard immunohistochemical techniques. Results. 26{\%} of the IPMNs labeled with Adnab-9 as compared to 0{\%} of pancreatic ductal cancers or surrounding benign tissues, (p <0.001) and 53{\%} of adenomas (p <0.025). Labeling in IPMNs was usually seen in the noninvasive epithelium suggesting that Adnab-9 is a premalignant marker in these lesions. Labeling of invasive IPMN's identified a group of patients with a superior overall survival (p = 0.027). Conclusion. Adnab-9 labeling-characteristics appear similar for both IPMNs and adenomatous polyps, suggesting that they are analogous lesions. Adnab-9 labeling may also be a useful prognostic marker for invasive intraductal papillary mucinous neoplasms.",
keywords = "Colorectal cancer, Immunostaining, Intraductal papillary mucinous neoplasms, Monoclonal antibody, Pancreatic ductal cancer, Severely dysplastic adenomatous colonic polyps",
author = "Martin Tobi and James Hatfield and Volkan Adsay and Katherine Galagan and Richard Kozarek and Mitsuhiro Inagaki and Shinichi Kasai and Yoshihiko Tokusashi and Takeshi Obara and Hruban, {Ralph H} and John Lough and Barkun, {Alan N.} and Mansour Jabbari and Rafiq Sheikh and Boris Ruebner and Lawson, {Michael J.} and Edgar Ben-Josef and Suzanne Fligiel",
year = "2001",
language = "English (US)",
volume = "29",
pages = "141--150",
journal = "Journal of Gastrointestinal Cancer",
issn = "1941-6628",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Prognostic significance of the labeling of Adnab-9 in pancreatic intraductal papillary mucinous neoplasms

AU - Tobi, Martin

AU - Hatfield, James

AU - Adsay, Volkan

AU - Galagan, Katherine

AU - Kozarek, Richard

AU - Inagaki, Mitsuhiro

AU - Kasai, Shinichi

AU - Tokusashi, Yoshihiko

AU - Obara, Takeshi

AU - Hruban, Ralph H

AU - Lough, John

AU - Barkun, Alan N.

AU - Jabbari, Mansour

AU - Sheikh, Rafiq

AU - Ruebner, Boris

AU - Lawson, Michael J.

AU - Ben-Josef, Edgar

AU - Fligiel, Suzanne

PY - 2001

Y1 - 2001

N2 - Background. Pancreatic intraductal papillary mucinous neoplasms (IPMN), morphologically resembling colonic adenomas, often have an indefinable malignant potential. We used a monoclonal antibody (MAb) raised against colonic adenomas, Adnab-9, to identify patients with a better prognosis. Methods. We assessed Adnab-9-labeled sections of these neoplasms from 50 patients, 13 pancreatic adenocarcinomas, and 32 colonic adenomas using standard immunohistochemical techniques. Results. 26% of the IPMNs labeled with Adnab-9 as compared to 0% of pancreatic ductal cancers or surrounding benign tissues, (p <0.001) and 53% of adenomas (p <0.025). Labeling in IPMNs was usually seen in the noninvasive epithelium suggesting that Adnab-9 is a premalignant marker in these lesions. Labeling of invasive IPMN's identified a group of patients with a superior overall survival (p = 0.027). Conclusion. Adnab-9 labeling-characteristics appear similar for both IPMNs and adenomatous polyps, suggesting that they are analogous lesions. Adnab-9 labeling may also be a useful prognostic marker for invasive intraductal papillary mucinous neoplasms.

AB - Background. Pancreatic intraductal papillary mucinous neoplasms (IPMN), morphologically resembling colonic adenomas, often have an indefinable malignant potential. We used a monoclonal antibody (MAb) raised against colonic adenomas, Adnab-9, to identify patients with a better prognosis. Methods. We assessed Adnab-9-labeled sections of these neoplasms from 50 patients, 13 pancreatic adenocarcinomas, and 32 colonic adenomas using standard immunohistochemical techniques. Results. 26% of the IPMNs labeled with Adnab-9 as compared to 0% of pancreatic ductal cancers or surrounding benign tissues, (p <0.001) and 53% of adenomas (p <0.025). Labeling in IPMNs was usually seen in the noninvasive epithelium suggesting that Adnab-9 is a premalignant marker in these lesions. Labeling of invasive IPMN's identified a group of patients with a superior overall survival (p = 0.027). Conclusion. Adnab-9 labeling-characteristics appear similar for both IPMNs and adenomatous polyps, suggesting that they are analogous lesions. Adnab-9 labeling may also be a useful prognostic marker for invasive intraductal papillary mucinous neoplasms.

KW - Colorectal cancer

KW - Immunostaining

KW - Intraductal papillary mucinous neoplasms

KW - Monoclonal antibody

KW - Pancreatic ductal cancer

KW - Severely dysplastic adenomatous colonic polyps

UR - http://www.scopus.com/inward/record.url?scp=0035739657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035739657&partnerID=8YFLogxK

M3 - Article

C2 - 12067217

AN - SCOPUS:0035739657

VL - 29

SP - 141

EP - 150

JO - Journal of Gastrointestinal Cancer

JF - Journal of Gastrointestinal Cancer

SN - 1941-6628

IS - 3

ER -